University of Aberdeen and Scotia Biologics Limited

To develop, optimise, scale-up and commercialise two novel antibodies for use as flow cytometry reagents, improving the current method for the analysis of cell death. This will lead to advances in the diagnosis and treatment of various diseases including inflammatory diseases and cancer.